Cascadian Therapeutics, Inc. is on the Cruelty Free Investing use of animals list because they conduct pre-clinical studies of their drugs on animals to assess a product’s safety profile.
The following company report cites that, “Tucatinib is a mid-stage clinical development candidate and the risks associated with its development are significant. Promising pre-clinical data in animal models and early clinical data may not be predictive of later clinical trial results. ” (Page 29) Read the full document.
Cascadian Therapeutics, Inc. is a clinical-stage biopharmaceutical company, engages in the development of therapeutic products for the treatment of cancer. Its lead product candidate ONT-380, is an orally active and selective small-molecule HER2 inhibitor. It also develops preclinical product candidates in oncology using Chk1 kinase inhibitor and protocell technology. The company was founded on September 7, 2007 and is headquartered in Seattle, WA. [Source: MarketWatch]
Company Website: http://www.cascadianrx.com